Michelle Pelle, MD
Dermatology · San Diego, CANPI 1043252786
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $296 of the $404 with a category attached, or 73.3%. 9 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 30.8% of the total. 2025 is the largest year on record at $193, 2.5 times the $77 reported in 2019. That places this record below the midpoint for dermatology clinicians in CA, where the typical reported total is $1,655.
Across 13 payments — averaging $31.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$125
- Galderma Laboratories, L.p.$60
- LEO Pharma Inc.$60
- Johnson & Johnson$48
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$39
- Novartis$26
- plus $46 from 3 others
Across 631 payments — averaging $2802.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$444K
- E.r. Squibb & Sons, L.L.C.$300K
- Pfizer$266K
- Incyte Corporation$193K
- Novartis$188K
- Janssen Research & Development, LLC$156K
- plus $222K from 5 others
What the payments were for
- Food & beverage$29673%
- Education$10827%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Galderma Laboratories, L.p. | 3 | $60 |
| LEO Pharma Inc. | 1 | $60 |
| Johnson & Johnson | 1 | $48 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $39 |
| Novartis | 1 | $26 |
| AbbVie | 1 | $25 |
| Revance Therapeutics, Inc. | 1 | $15 |
| Pfizer | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$125
How this compares
$404 in reported general payments places this provider in the 25th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SiliqBrodalumab | 23 | $120,482 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $94,771 |
| RayosPrednisone | 11 | $27,575 |
| Bexarotene | 12 | $16,892 |
| Acitretin | 33 | $7,349 |
| Clobetasol Propionate | 69 | $3,334 |
| Fluorouracil | 65 | $3,222 |
| Doxycycline Monohydrate | 93 | $2,084 |
| Gentamicin Sulfate | 88 | $1,500 |
| Tretinoin | 38 | $1,468 |
| GriseofulvinGriseofulvin, Microsize | 23 | $1,420 |
| Clindamycin Phosphate | 42 | $1,135 |
| ValacyclovirValacyclovir Hcl | 17 | $1,101 |
| Hydroxychloroquine Sulfate | 22 | $889 |
| Halobetasol Propionate | 17 | $844 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq | $39 | $120,48223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,875 dermatology providers in California.
Other dermatology in San Diego
- Neal BhatiaSan Diego$2.5M
- Arisa OrtizSan Diego$261K
- Michael BradshawSan Diego$143K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.